FTC Requires Aurobindo to Divest Four Generic Drug Products to Complete $250 million Lannett Acquisition
The Federal Trade Commission moved to require Aurobindo Pharma Limited to divest four generic drug products in order to complete its $250 million acquisition of Lannett Company Inc., per the FTC's June 18 press release.
At a glance
- A proposed FTC order requires Aurobindo Pharma to divest four generic drug products, per the agency's June 18, 2026 release.
- The divestitures are a condition of Aurobindo's $250 million acquisition of Lannett Company Inc., per the FTC.
VERDICT — CONFIRMED
The Federal Trade Commission moved to require Aurobindo Pharma Limited to divest four generic drug products in order to complete its $250 million acquisition of Lannett Company Inc., per the FTC's June 18 press release.
Per the agency, the proposed consent order is intended to resolve anticompetitive concerns and protect American patients from higher drug costs. Divestiture orders of this kind are the FTC's standard remedy when a merger would otherwise combine overlapping product lines.
The order is proposed, not final, per the release — the divestitures stand as a condition of completing the deal. Which four generic products must be divested, the identity of any divestiture buyer, and the timeline for closing were not carried in the feed and remain unverified here.
Key facts on file
- A proposed FTC order requires Aurobindo Pharma to divest four generic drug products, per the agency's June 18, 2026 release.
- The divestitures are a condition of Aurobindo's $250 million acquisition of Lannett Company Inc., per the FTC.
